Will The Rally Continue? Arbutus Biopharma Corporation (NASDAQ:ABUS) Is In News

Arbutus Biopharma Corporation (NASDAQ:ABUS) is moving up slightly in the pre-open session on Wednesday.

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

  • announced that five abstracts have been accepted for presentation at the upcoming International Liver CongressTM (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) in June 2021.
  • Arbutus will hold a conference call at 8:00 AM ET, Monday June 28, 2021 to discuss the new data being presented at EASL.
  • The accepted abstracts include two oral presentations, one of which is a late breaker, and three poster presentations. The presentation details and schedules are as follows:
  • LBO-2764 – Title: Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression. Presenter: Prof. Man-Fung Yuen, D.Sc., M.D., Ph.D., Deputy Head of Department, Chief of Division of Gastroenterology and Hepatology, Master of Lap Chee, University of Hong Kong. Session: Late Breaker June 26, 2021 / 12:00 PM – 1:30 PM CET (6:00 AM – 7:30 AM ET). AB-729 Presentation Time: 1:15 PM CET (7:15 AM ET)
  • OS-595- Title: Preclinical antiviral profile of AB-836, a potent highly selective hepatitis B virus capsid inhibitor. Presenter: Dr. Nagraj Mani, Ph.D., Research Fellow, Arbutus Biopharma Corp. Session: Hepatitis B: Novel Therapeutic Approaches Session Date / Time: June 25, 2021 / 2:00 PM – 3:30 PM CET (8:00 AM – 9:30 AM ET). AB-836 Presentation Time: 2:45 PM CET (8:45 AM ET). Presentation available to ILC participants on June 21, 2021 at 10:00 AM CET (4:00 AM ET)             

Market Action

As of 8:18, ABUS stock is up by 1.05% to $2.89. So far the stock has traded 4.90K shares traded hands. The stock has been underperforming the broader market over the past six months with a fall of 28%.

Related Posts

About The Author